EJC Skin Cancer最新文献

{"title":"New Endpoints And Outcomes Of Immunotherapy In Patients With Advanced Melanoma: Results From The Real-World Study GEM1801","authors":"E. Muñoz-Couselo , G. Crespo , M.-Á. Berciano-Guerrero , J.L. Manzano , A. García Castaño , P. Ayala de Miguel , P. Cerezuela-Fuentes , J. Medina , C. Aguado de la Rosa , E. Espinosa , A. Soria , L. Gutiérrez Sanz , T. Puértolas , M. Majem , A. Martín-Carnicero , B. Rivas , A. Burjosa , K. Mujika , L.A. Fernández , J.C. Villa Guzmán , I. Márquez-Rodas","doi":"10.1016/j.ejcskn.2026.100873","DOIUrl":"10.1016/j.ejcskn.2026.100873","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100873"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatofibrosarcoma protuberans in South Africa: Outcomes of staged excision and peripheral and deep en face margin assessment (PDEMA) and recommendations for wide local excision margins","authors":"Vanessa D. Kriek ,&nbsp;Willem I. Visser ,&nbsp;Mercy Rop ,&nbsp;Jacob D. de Wet ,&nbsp;Johann de Wet ,&nbsp;Pieter J. du Plessis","doi":"10.1016/j.ejcskn.2026.101145","DOIUrl":"10.1016/j.ejcskn.2026.101145","url":null,"abstract":"<div><h3>Background</h3><div>Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive tumour with recurrence rates of 10–60% after wide local excision (WLE). Surgical excision with peripheral and deep en face margin assessment (PDEMA) offers superior cure rates (1.11%).</div></div><div><h3>Objective</h3><div>To report the outcomes of staged excision (SE) with PDEMA for DFSP in South Africa and to propose a pragmatic approach to selecting WLE margins when PDEMA is unavailable.</div></div><div><h3>Methods</h3><div>Nineteen DFSP patients underwent staged excision (SE) with PDEMA. Data collected included tumour and defect size, margin required for clearance, complications, recurrence, and tissue sparing. Using our margin-clearance data, we projected the defect sizes required for complete clearance with WLE and compared these with the actual defect sizes from our cases. Tissue preservation was calculated and analysed for statistical significance using non-parametric tests.</div></div><div><h3>Results</h3><div>Complete margin clearance was achieved in all cases, with no complications or recurrences at a median 35-month follow-up. DFSPs were stratified into three groups: a) small primary DFSP (&lt;1 cm diameter); b) large primary DFSP (&gt;1 cm diameter) and c) recurrent DFSP. Peripheral margins needed to clear all tumours: a) 2 cm, b) 4 cm, c) 5 cm. Tumour extension beyond the deep fascia was observed in all groups, suggesting that WLE depth should extend below the deep fascia if PDEMA is not utilised. SE with PDEMA achieved significant tissue preservation.</div></div><div><h3>Limitations</h3><div>The small sample size limits generalisability.</div></div><div><h3>Conclusions</h3><div>SE with PDEMA can be successfully implemented in South Africa. PDEMA ensures complete margin clearance, significant tissue preservation and a high cure rate. Where PDEMA is unavailable, stratifying DFSP by size and recurrence status can guide appropriate WLE margins. When WLE is performed, the deep excision margin should include a tissue layer deeper than the deep fascia.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 101145"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147944918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cryotherapy for actinic keratoses: A cross-sectional survey of real-world clinical practice","authors":"Husna Moola ,&nbsp;Susanna Kannenberg ,&nbsp;Willem Izak Visser","doi":"10.1016/j.ejcskn.2026.101129","DOIUrl":"10.1016/j.ejcskn.2026.101129","url":null,"abstract":"<div><div>Cryotherapy is commonly used to treat actinic keratoses (AKs), yet recommended protocols vary across studies and reference texts. This cross-sectional survey evaluated real-world cryotherapy practices among 81 clinicians. Mean freeze duration per cycle was 7.98 s for thin AKs and 10.88 s for thick AKs. Two cycles were used more often for thick lesions. Freeze duration and cycle number were guided mainly by lesion characteristics and visual cues rather than strict timing. These findings describe contemporary practice patterns and provide a pragmatic reference point for cryotherapy training and clinical decision-making.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 101129"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147537855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Living with advanced or metastatic melanoma: A patient-driven conceptual model","authors":"Shehan McFadden,&nbsp;Swaha Pattanaik,&nbsp;Joanne Buzaglo,&nbsp;James Turnbull,&nbsp;Adyb Baakili,&nbsp;Sophie Van Tomme","doi":"10.1016/j.ejcskn.2026.101154","DOIUrl":"10.1016/j.ejcskn.2026.101154","url":null,"abstract":"<div><h3>Background</h3><div>Patients with advanced/metastatic melanoma experience various symptoms that significantly impact on their health-related quality of life (HRQoL). However, a comprehensive conceptual model (CM) has not been developed to capture the full spectrum of patient-reported symptoms and impacts. This study aimed to develop a patient-centered CM for advanced/metastatic melanoma.</div></div><div><h3>Methods</h3><div>Targeted literature review and clinician interviews informed the development of a preliminary CM. To refine and finalize the CM, semi-structured interviews were conducted with US-based patients diagnosed with advanced or metastatic melanoma. Furthermore, the Functional Assessment of Cancer Therapy-Melanoma (FACT-M), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), pain Numeric Rating Scale (NRS), and itch NRS were chosen for cognitive debriefing of patients.</div></div><div><h3>Results</h3><div>The preliminary CM was developed using 10 articles and five patient blogs. Interviews with three clinicians identified 15 priority symptoms and one key impact. Subsequently, interviews with 20 patients revealed additional 70 symptoms and 47 impacts. Frequently reported and bothersome symptoms included fatigue (n = 19), lumps or nodes (n = 14), fever (n = 13), joint pain (n = 13), changes in vision (n = 13), chills (n = 12), and itching (n = 11). Debriefing of FACT-M, EORTC QLQ-C30, pain NRS, and itch NRS items revealed that most participants found these measures clear, easy to understand, and relevant to their experiences with advanced/metastatic melanoma.</div></div><div><h3>Conclusions</h3><div>This study presents the first patient-informed CM for advanced/metastatic melanoma, offering a comprehensive overview of the disease- and treatment-related symptoms and impacts, which can guide the selection of meaningful outcome measures in future clinical trials.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 101154"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148565617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel prognostic model for patients with metastatic cutaneous melanoma","authors":"T. Hackmann ,&nbsp;B. Perić ,&nbsp;L. de Wreede ,&nbsp;E. Kapiteijn ,&nbsp;M. Donia ,&nbsp;I.M. Svane ,&nbsp;E. Steyerberg ,&nbsp;M. Wouters ,&nbsp;4D PICTURE1","doi":"10.1016/j.ejcskn.2026.100790","DOIUrl":"10.1016/j.ejcskn.2026.100790","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100790"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Features and Treatment Outcomes of Primary Unknown Melanoma: A Single-Center Retrospective Analysis of Eight Advanced Cases","authors":"S. Jinnai,&nbsp;A. Takahashi","doi":"10.1016/j.ejcskn.2026.100807","DOIUrl":"10.1016/j.ejcskn.2026.100807","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100807"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Melanoma during pregnancy: report of 3 cases","authors":"E. Zavattaro ,&nbsp;F. Zottarelli ,&nbsp;A.P. Sponghini ,&nbsp;I. Taglialatela ,&nbsp;P. Savoia","doi":"10.1016/j.ejcskn.2026.100860","DOIUrl":"10.1016/j.ejcskn.2026.100860","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100860"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Onset of Poliosis is linked to Durable Response to Immune-Checkpoint Blockade in Metastatic Melanoma Patients: A Multicenter Case Series","authors":"A. Brekner,&nbsp;A. Lepper,&nbsp;M. Kaufhold,&nbsp;J. Veeser,&nbsp;J. Dietzel,&nbsp;N. Laubach,&nbsp;S. Grabbe,&nbsp;H. Stege,&nbsp;M. Haist","doi":"10.1016/j.ejcskn.2026.100876","DOIUrl":"10.1016/j.ejcskn.2026.100876","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100876"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of recurrence and recurrence-free survival using Machine Learning approaches among stage I–II and III melanoma patients in Serbia","authors":"I. Tanasković ,&nbsp;I. Salatić ,&nbsp;M. Recalde ,&nbsp;B. Dujović ,&nbsp;S. Matković ,&nbsp;M. Đurkić ,&nbsp;J. Filipović ,&nbsp;A. Ivezić ,&nbsp;B. Nikolin ,&nbsp;N. Kolović ,&nbsp;E. Milosavljević ,&nbsp;M. Petronijević ,&nbsp;M. Balić ,&nbsp;A. Popović ,&nbsp;D. Manioti ,&nbsp;A. Mijatovic Mrdja ,&nbsp;L. Kandolf ,&nbsp;B. Rakić","doi":"10.1016/j.ejcskn.2026.100883","DOIUrl":"10.1016/j.ejcskn.2026.100883","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 100883"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147720416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune-related pneumonitis: A retrospective analysis of corticosteroid requirements and the role of hydroxychloroquine in melanoma patients","authors":"Tanja Patricia Eicher ,&nbsp;Lisa Hofer ,&nbsp;Joanna Mangana ,&nbsp;Reinhard Dummer ,&nbsp;Lukas Kraehenbuehl","doi":"10.1016/j.ejcskn.2026.101142","DOIUrl":"10.1016/j.ejcskn.2026.101142","url":null,"abstract":"<div><h3>Background/Objectives</h3><div>Expanding use of immune checkpoint blockade (ICB) has led to a rise in immune-related adverse events, including immune-related pneumonitis (IRP), a potentially fatal condition. Corticosteroids remain first-line therapy for IRP, but prolonged use may reduce ICB efficacy, cause toxicity, and fail in refractory cases. Hydroxychloroquine (HCQ) has shown steroid-sparing effects in immune-related arthritis, yet its role in IRP remains unclear. This study evaluated HCQ as an adjunct to corticosteroid-based IRP management in melanoma patients.</div></div><div><h3>Methods</h3><div>This retrospective single-centre cohort study included adult patients with metastatic melanoma treated with ICB at the University Hospital Zurich from November 2014 to January 2025 who developed Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 2 IRP. Patients were stratified by HCQ exposure. The primary outcome was cumulative corticosteroid dose; secondary outcomes included steroid duration, average daily dose, ICB resumption, and adverse events.</div></div><div><h3>Results</h3><div>Among 46 melanoma patients with CTCAE grade ≥ 2 IRP, 10 patients received HCQ and 36 did not. HCQ-treated patients had higher cumulative steroid doses (median 4514 mg vs. 1627 mg) and longer therapy duration (131 vs. 85 days), without statistical significance. Following HCQ initiation, average daily corticosteroid dose declined from 88.9 mg/d to 23.3 mg/d, similar to HCQ-unexposed patients (23.1 mg/d). Notably, two HCQ-treated patients achieved IRP resolution without corticosteroids or further immunomodulation.</div></div><div><h3>Conclusions</h3><div>Adjunctive HCQ was well-tolerated, with only one patient experiencing mild side effects. Limitations (small sample size, indication bias, confounding) preclude definitive conclusions. A prospective, randomized study is warranted to define HCQ’s therapeutic role alongside ICB therapy.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"4 ","pages":"Article 101142"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147740093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}